Peptides and hair loss: copper, thymosin β4 and biomimetics against the evidence

The hair cycle: where peptides act

The follicle cycles through four phases: anagen (growth, highly mitotic), catagen (regression), telogen (rest) and exogen (shedding). At any time about 9% of follicles are in telogen; inflammation, hormones, stress, nutritional deficiency and some drugs push the anagen-to-telogen transition, while blood flow, direct follicle stimulation and growth factors favor the return to anagen¹. Two conditions dominate the clinic: androgenetic alopecia, an androgen-dependent miniaturization of the follicle in which scalp dihydrotestosterone is implicated³, and telogen effluvium, which appears about 3 months after a trigger and usually begins to recover at 3–6 months, with full recovery around 12². The peptides studied act on the dermal papilla, follicle stem cells and the matrix that anchors the hair.

The benchmark: minoxidil and finasteride

Any peptide is measured against these two drugs. In two one-year trials in 1553 men, finasteride 1 mg/day increased hair counts by 107 and 138 hairs vs placebo at 1 and 2 years, in a 5.1 cm² vertex area; with placebo, hair loss progressed³. In 393 men, 5% topical minoxidil produced 45% more regrowth than 2% at 48 weeks⁴. Low-dose oral minoxidil has gained ground: a meta-analysis of 4 randomized trials (279 patients) found no difference from topical in hair density or diameter, though more hypertrichosis (RR 2.01)⁵; another found no significant blood-pressure change, a heart-rate increase of 2.67 beats per minute, and hypertrichosis accounted for 34.6% of discontinuations⁶.

Copper peptides: from the cultured follicle to the scalp

The most-cited laboratory finding is not for GHK-Cu but for its sister molecule, AHK-Cu (L-alanyl-L-histidyl-L-lysine-Cu²⁺): at 10⁻¹² to 10⁻⁹ M it stimulated elongation of human hair follicles ex vivo and proliferation of dermal papilla cells; at 10⁻⁹ M it raised the Bcl-2/Bax ratio and reduced cleaved caspase-3 and PARP, suggesting an anti-apoptotic effect⁷. The mechanism of GHK-Cu in skin is covered in GHK-Cu: the mechanism of action, step by step and the technical sheet in GHK-Cu.

In humans, the data point the same way:

• 5-ALA + GHK (2016): 45 men with androgenetic alopecia, daily application for 6 months of a complex of 5-aminolevulinic acid and GHK (the abstract does not state copper). Hair counts rose by 52.6 and 71.5 with the two concentrations vs 9.6 with placebo, with no difference in length or thickness⁸.
• Minoxidil + dutasteride + copper peptides by tattooing (2025): retrospective analysis of 7 men who had not responded to at least 1 year of standard treatment. Five monthly sessions with a solution of 0.5% minoxidil, 0.1% dutasteride and 1.2% copper peptides. Median top-quadrant SALT score fell from 40.0% to 7.5% (P < .001) and median regrowth was 26.5%, vs 10% in a prior 3-session series without copper (P = .0025), with no scarring or infection⁹.
• Intradermal growth-factor formulation (2018): open-label study of 1000 patients with a mix of VEGF, bFGF, IGF, KGF, thymosin β4 and copper tripeptide-1, 8 sessions every 3 weeks; reduced shedding on the pull test in 83% and an increase in total hair count at 1 year (P = 0.002)¹⁰.

The authors of the tattooing study conclude that the procedure "appears to be preliminarily effective" and that further studies are warranted⁹.

Thymosin β4: the follicle in animal models

Here precision about the molecule matters. The hair studies use full-length thymosin β4, 43 amino acids long. In normal rats and mice it stimulated hair growth; at nanomolar concentrations it increased migration and differentiation of clonogenic follicle keratinocytes, closely related to bulge stem cells, and raised MMP-2¹¹. In genetically modified mice, epidermal Tβ4 overexpression sped regrowth after depilation and gene knockout slowed it, with parallel changes in VEGF and in P38, ERK and AKT phosphorylation¹². A 2021 review adds that exogenous Tβ4 increased cashmere production in goats by increasing secondary follicles¹³. We found no hair studies in PubMed with the Ac-LKKTETQ fragment sold as short-chain TB-500; the difference is explained in TB-500 is not thymosin beta-4, and the TB-500 sheet states which molecule each finding refers to. In humans, Tβ4 appears only as one of the six components of the intradermal formulation above¹⁰.

Biomimetic peptides: shampoos, lotions and PRP

Hair cosmetics use peptides under trade names. According to a 2025 review, Capixyl combines acetyl tetrapeptide-3 with biochanin A, and Procapil combines biotinoyl tripeptide-1 (biotinyl-GHK) with apigenin and oleanolic acid¹⁵. The trials with verifiable abstracts are these:

• Acetyl tetrapeptide-3 (2020): 24-week triple-blind randomized trial in 32 patients with mild to moderate androgenetic alopecia. A combination of biochanin A, acetyl tetrapeptide-3 and ginseng increased terminal hair by 8.3% vs 8.7% with 3% minoxidil, with no significant difference; one patient developed eczema with minoxidil and none with the lotion¹⁴.
• Acetyl tetrapeptide-2 in telogen effluvium (2021): 100 randomized women, open-label trial. A lotion with creatine, acetyl tetrapeptide-2 and B vitamins reduced total hairs shed at week 8 (P = 0.0392) and telogen hair density (P = 0.0465) more than mild shampoo alone².
• Procapil with PRP (2024): quasi-experimental study in 160 patients; adding 5% Procapil to 4 PRP sessions was associated with better dermatologist and patient scores at 6 months (p < 0.05)¹⁶.
• Redensyl, Capixyl and Procapil vs 5% minoxidil: the 2025 review summarizes a randomized trial in 106 men over 24 weeks, with a better investigator score in the combination group (64.7% vs 25.5%)¹⁵.

Hair loss on GLP-1 drugs: an effluvium with its own name

This is the new consultation. A 2026 meta-analysis of 9 interventional studies (7 randomized, 4114 users) found a 3.25-fold higher risk of hair loss than with placebo (95% CI 1.44–7.36) and a rate of 3.9%¹⁷. Another, with 17 studies and 1,091,743 exposures, estimated 40% more non-scarring alopecia (OR 1.40), with associations for telogen effluvium (aOR 1.76) and androgenetic alopecia (aOR 1.64), not for alopecia areata; the authors attribute it mainly to weight-loss-related micronutrient deficiency and advise avoiding premature discontinuation of the drug¹⁸. Telogen effluvium is usually reversible, and management focuses on identifying the trigger, explaining and offering supportive therapies¹⁹. For the rest of the skin on GLP-1 drugs, see The "GLP-1 face".

New targets: PTD-DBM and the Wnt pathway

The protein CXXC5 brakes the Wnt/β-catenin pathway and is increased in miniaturized follicles of human balding scalp. A competitor peptide that blocks its binding to Dishevelled accelerated hair regrowth and wound-induced follicle neogenesis in mice²⁰. That peptide, PTD-DBM, reversed prostaglandin D2-induced hair loss in mice, and the same group described CXXC5 as a mediator of dihydrotestosterone-induced hair loss²¹. The corresponding author heads the company licensed to develop it²¹. We found no published clinical trials of PTD-DBM in PubMed.

Where the evidence ends

• The peptide is rarely tested alone: biomimetic lotions include vitamins, minerals or other actives, and the 2025 review notes small samples, lack of comparison with standard treatments and conflicts of interest¹⁵. The authors of the telogen effluvium study are affiliated with a dermocosmetics company².
• The molecule changes from study to study: AHK-Cu ex vivo⁷, GHK with no stated copper⁸, unspecified "copper peptides"⁹ and six-component mixes¹⁰ are not equivalent to GHK-Cu.
• Weak designs: the tattooing study was retrospective, with 7 men, no control group and no trichoscopic measurement⁹; the 1000-patient study was open-label and single-arm¹⁰.
• Thymosin β4 and PTD-DBM are animal data: rats, mice and goats^1112132021.
• No robust head-to-head comparison: the only trial against minoxidil with a PubMed abstract had 32 patients¹⁴.